Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 8/20 | 1.00 |
| ▸ | CA9 | Q16790 | 8/20 | 1.00 |
| ▸ | CA1 | P00915 | 5/20 | 1.00 |
| ▸ | CA2 | P00918 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | GLA | P06280 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | IL2 | P60568 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.56 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.56 |
| ▸ | ALDH1B1 | P30837 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260974 | 1.00 | CA12 (1.00) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL10048269 | 1.00 | CA12 (1.00) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL145332 | 1.00 | CA12 (1.00) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL15484273 | 1.00 | CA12 (1.00) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL1526661 | 1.00 | CA12 (1.00) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL15745917 | 1.00 | CA12 (1.00) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL2319034 | 1.00 | CA12 (1.00) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL165912 | 1.00 | CA12 (1.00) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL152641 | 1.00 | CA12 (1.00) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL1356276 | 1.00 | CA12 (1.00) | CA12CA9CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1573042-A1 | METHOD FOR DETERMINING THE ENZYMATIC STATUS OF HUMAN SKIN IN VITRO | Henkel Kommanditgesellschaft auf Aktien (DE) | 2005-09-14 | — | — | EP | claimed |
| WO-2004058991-A1 | METHOD FOR DETERMINING THE ENZYMATIC STATUS OF HUMAN SKIN IN VITRO | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2004-07-15 | — | — | WO | claimed |
| EP-0954560-A1 | METHOD AND MEDIUM FOR DETECTING VANCOMYCIN-RESISTANT ENTEROCOCCUS | IDEXX LABORATORIES, INC. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1998004674-A1 | METHOD AND MEDIUM FOR DETECTING VANCOMYCIN-RESISTANT $i(ENTEROCOCCUS) | IDEXX LABORATORIES, INC. (US) | 1998-02-05 | — | — | WO | claimed |
| EP-4408533-A1 | OXIMES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | Zevra Denmark A/S (DK) | 2024-08-07 | — | — | EP | disclosed |
| US-20240076660-A1 | GENE CORRECTION OF POMPE DISEASE AND OTHER AUTOSOMAL RECESSIVE DISORDERS VIA RNA-GUIDED NUCLEASES | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2024-03-07 | — | — | US | disclosed |
| US-11739320-B2 | Gene correction of Pompe disease and other autosomal recessive disorders via RNA-guided nucleases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2023073531-A1 | GLYCOCONJUGATED DRUG FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS (CONICET) (AR) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023053008-A1 | OXIMES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | KEMPHARM DENMARK A/S (DK) | 2023-04-06 | — | — | WO | disclosed |
| WO-2022271944-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF GAUCHER DISEASE | AVROBIO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220281908-A1 | 8-FLUORO-4-ALKYLUMBELLIFERYL ALPHA-D-GLUCOPYRANOSIDE, BIOLOGICAL STERILIZATION INDICATOR INCLUDING THE SAME AND ITS USE IN A METHOD OF DETERMINING EFFICACY OF A STERILIZATION PROCESS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2022-09-08 | — | — | US | disclosed |
| WO-2021059058-A1 | 8-FLUORO-4-ALKYLUMBELLIFERYL ALPHA-D-GLUCOPYRANOSIDE, BIOLOGICAL STERILIZATION INDICATOR INCLUDING THE SAME AND ITS USE IN A METHOD OF DETERMINING EFFICACY OF A STERILIZATION PROCESS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2021-04-01 | — | — | WO | disclosed |
| EP-0685458-A1 | Glycolipid analogues as glucosidase inhibitors | SEIKAGAKU KOGYO KABUSHIKI KAISHA (SEIKAGAKU CORPORATION) (JP) | 1995-12-06 | — | — | EP | disclosed |
| US-5089395-A | High speed qualitative, quantitative analysis | UNIVERSITY OF CINCINNATI (US) | 1992-02-18 | — | — | US | disclosed |
| EP-0173255-B1 | OLIGOSACCHARIDE DERIVATIVES AND THEIR USE AS SUBSTRATE FOR MEASURING ALPHA-AMYLASE ACTIVITY | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1991-04-17 | — | — | EP | disclosed |
| US-4762917-A | AMINO SUBSTITUTED | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1988-08-09 | — | — | US | disclosed |
| EP-0215066-A1 | VIABLE MICROORGANISM DETECTION BY INDUCED FLUORESCENCE | UNIVERSITY OF CINCINNATI (US) | 1987-03-25 | — | — | EP | disclosed |
| WO-1986005206-A1 | VIABLE MICROORGANISM DETECTION BY INDUCED FLUORESCENCE | UNIVERSITY OF CINCINNATI (US) | 1986-09-12 | — | — | WO | disclosed |
| EP-0173255-A2 | Oligosaccharide derivatives and their use as substrate for measuring alpha-amylase activity | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1986-03-05 | — | — | EP | disclosed |
| US-4231750-A | Methods for performing chemical assays using fluorescence and photon counting | DIAGNOSTIC REAGENTS, INC. (US) | 1980-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281908-A1 | 8-FLUORO-4-ALKYLUMBELLIFERYL ALPHA-D-GLUCOPYRANOSIDE, BIOLOGICAL STERILIZATION INDICATOR INCLUDING THE SAME AND ITS USE IN A METHOD OF DETERMINING EFFICACY OF A STERILIZATION PROCESS | ALPG, UNG, UGDH | CA12 1975/4885CA9 1573/4885CA1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.